News

R. Presley Swann, MD discussed his preference for CPNBs when treating his patient's post-operative pain.

A new phase 1 trial will study a DNA vaccine cocktail against HIV.

While DEX implants improved BCVA in patients with DME, new data shows the improvement diminished over time.

Study findings indicated that the BRUKER MALDI Biotyper CA system was able to identify the pathogen 100% of the time.

Dr Ali Fatemi, MD, of Kennedy Krieger Institute and John Hopkins University, describes the “Awesome Disease” (LBSL) and how a young girl now inspires his research.

A positive PartoSure test was more than 4 times as reliable as a positive fetal fibronectin test, the only other FDA-approved test for assessing the risk of preterm delivery.

At the 70th AAN Annual Meeting this morning Summit Therapeutics plc presented new 24-week interim data from PhaseOut DMD, its Phase 2 trial of ezutromid in Duchenne.

The FDA approved fostamatinib disodium hexahydrate (Tavalisse) tablets for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia. RDR discusses with Dr James Bussel.

A group of researchers is planning an ambitious project that could have implications for diseases like diabetes: to build a complete model of the pancreatic ß cell.

New data has shown that using the anti-VEGF agent in patients with AMD that are older than 85 does not increase their risk of heart attack or stroke.

Researchers from GlaxoSmithKline will collect data from a group of young children treated with Strimvelis in Milan.

On Wednesday, it was announced that Synlogic had initiated and dosed the first subject in its Phase 1/2a study of SYNB1618 for the treatment of phenylketonuria.

The 10,000-plus participant IMPACT study reported the triple-combination therapy fared better in exacerbation reduction than FF/VI or FF/UMEC.

Monthly seizures were reduced by about 40% in those taking Epidiolex.

The first patient was enrolled in a Phase 3 clinical trial of amifampridine phosphate (Firdapse) in patients with mmuscle-specific kinase (MuSK) antibody positive myasthenia gravis (MuSK-MG).

After 3 months, half of the patients reported no substance abuse, while the number of patients using drop to 2 (10%).

Dystrophic epidermolysis bullosa (DEB) treatment granted OMPD in Europe.

The addition of ribavirin to direct-acting antiviral treatment of HCV with cryoglobulinemia aided to achieving immunological response.

Two recent studies on surgical attrition have unveiled the factors that impact dropout rates and timing, highlighting the need for better guidance and early intervention for medical students entering surgical training.

According to data presented at the Annual Neuromuscular Translational Research Conference, researchers found that repeat dosing of CAP-1002 results in increased exercise performance in a disease model of Duchenne muscular dystrophy.

Could valbenazine or extract of Ginkgo biloba be the next therapy to come down the pipeline for the antipsychotic-induced condition?

As the number of primary care physicians shrinks, nurse practitioners have a unique opportunity to fill gaps in care.

HCV heightens the risk for kidney disease but, the disease's treatment improves rates of survival in patients on hemodialysis.

An analysis of 40-plus trials report that the closed loop system care can be the difference in 2.5 extra hours of daily normoglycemia.

Approximately 1 in every 5 men develop a urinary stricture, with urological procedures pertaining to the treatment anticipated to skyrocket with the aging of the baby boomer generation.

Findings indicate that the CD32 molecule is not preferential biomarker to identify HIV silent reservoirs, but instead identifies cells that are actively infected in spite of ART.

At the most recent American Lung Association LUNGFORCE expo, RDR sat down with Carly Ornstein to discuss the new resources made available by the ALA to individuals affected by lung fibrosis.

The first patient was dosed in X-linked retinitis pigmentosa (XLRP) treatment.

While its safety profile was lessened, celecoxib, in comparison with naproxen and ibuprofen, remained favorable when taken with aspirin.

Positive Phase 1b/2a trial results for RT001 in patients with Friedreich’s ataxia were published this morning in the online journal Movement Disorders.